Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Urinary microRNAs and Their Significance in Prostate Cancer Diagnosis: A 5-Year Update

J. Juracek, M. Madrzyk, M. Stanik, O. Slaby

. 2022 ; 14 (13) : . [pub] 20220628

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22023817

Grantová podpora
NV18-03-00360 Ministry of Health of the Czech Republic

Current routine screening methods for the diagnosis of prostate cancer (PCa) have significantly increased early detection of the disease but often show unsatisfactory analytical parameters. A class of promising markers represents urinary microRNAs (miRNAs). In the last five years, there has been an extensive increase in the number of studies on this topic. Thus, this review aims to update knowledge and point out technical aspects affecting urinary miRNA analysis. The review of relevant literature was carried out by searching the PubMed database for the keywords: microRNA, miRNA, urine, urinary, prostate cancer, and diagnosis. Papers discussed in this review were retrieved using PubMed, and the search strategy was as follows: (urine OR urinary) WITH (microRNA OR miRNA) AND prostate cancer. The search was limited to the last 5 years, January 2017 to December 2021. Based on the defined search strategy, 31 original publications corresponding to the research topic were identified, read and reviewed to present the latest findings and to assess possible translation of urinary miRNAs into clinical practice. Reviews or older publications were read and cited if they valuably extended the context and contributed to a better understanding. Urinary miRNAs are potentially valuable markers for the diagnosis of prostate cancer. Despite promising results, there is still a need for independent validation of exploratory data, which follows a strict widely accepted methodology taking into account the shortcomings and factors influencing the analysis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023817
003      
CZ-PrNML
005      
20221209092305.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers14133157 $2 doi
035    __
$a (PubMed)35804929
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Juracek, Jaroslav $u Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic $1 0000000199452530
245    10
$a Urinary microRNAs and Their Significance in Prostate Cancer Diagnosis: A 5-Year Update / $c J. Juracek, M. Madrzyk, M. Stanik, O. Slaby
520    9_
$a Current routine screening methods for the diagnosis of prostate cancer (PCa) have significantly increased early detection of the disease but often show unsatisfactory analytical parameters. A class of promising markers represents urinary microRNAs (miRNAs). In the last five years, there has been an extensive increase in the number of studies on this topic. Thus, this review aims to update knowledge and point out technical aspects affecting urinary miRNA analysis. The review of relevant literature was carried out by searching the PubMed database for the keywords: microRNA, miRNA, urine, urinary, prostate cancer, and diagnosis. Papers discussed in this review were retrieved using PubMed, and the search strategy was as follows: (urine OR urinary) WITH (microRNA OR miRNA) AND prostate cancer. The search was limited to the last 5 years, January 2017 to December 2021. Based on the defined search strategy, 31 original publications corresponding to the research topic were identified, read and reviewed to present the latest findings and to assess possible translation of urinary miRNAs into clinical practice. Reviews or older publications were read and cited if they valuably extended the context and contributed to a better understanding. Urinary miRNAs are potentially valuable markers for the diagnosis of prostate cancer. Despite promising results, there is still a need for independent validation of exploratory data, which follows a strict widely accepted methodology taking into account the shortcomings and factors influencing the analysis.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Madrzyk, Marie $u Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic $1 0000000233071230 $7 xx0279656
700    1_
$a Stanik, Michal $u Department of Urologic Oncology, Clinic of Surgical Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic $u Department of Biology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 13 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35804929 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20221209092257 $b ABA008
999    __
$a ind $b bmc $g 1854036 $s 1175105
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 13 $e 20220628 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a NV18-03-00360 $p Ministry of Health of the Czech Republic
LZP    __
$a Pubmed-20221010

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...